![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The advent of catheter ablation has revolutionized the treatment of supraventricular cardiac arrhythmias, including in the last few years, atrial fibrillation. The discovery of electrically active sleeves of atrial myocardium extending into the pulmonary veins has led to the development of pulmonary vein ostial ablation, with the aim of electrically isolating or ‘walling-off’ the arrhythmogenic tissue. Despite different innovations, the most commonly used technique is the composite multiple-point ablation lesion created with a fundamentally simple radiofrequency energy-delivering ablation catheter. The high recurrence rate and low efficacy of current ablation procedures may be traced in large part to the inherent variability in individual lesion size with this technology. Arguably, real-time lesion monitoring, optimization and prediction are necessary to achieve significant improvements in efficacy and safety for catheter ablation of atrial fibrillation.
Financial & competing interests disclosure
Dipen Shah is a member of the Scientific Advisory Board and a stockholder of Endosense SA, Geneva, who have developed a catheter mounted real-time contact force sensor. He reports receiving research grants and speaking honoraria from Biosense Webster, St Jude, Medtronic and Bard. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.